Booster dose: Bharat Biotech's nasal vaccine may be used with Covaxin

Bharat Biotech is working on a three-legged clinical trial for its intranasal vaccine BBV154, which is in phase two. The Hyderabad-based firm is testing the efficacy of a combination in three modes – two intranasal shots, first a Covaxin shot followed by the nasal vaccine, and Covaxin following a nasal shot.   The idea is to see which combination induces better and long-lasting immune response. Therefore, the intranasal vaccine could be used as a combination with the intramuscular Covaxin shot.   “While the nasal vaccine can be administered as two shots, the company i.....
Bharat Biotech is working on a three-legged clinical trial for its intranasal vaccine BBV154, which is in phase two. The Hyderabad-based firm is testing the efficacy of a combination in three modes – two intranasal shots, first a Covaxin shot followed by the nasal vaccine, and Covaxin following a nasal shot.

 

The idea is to see which combination induces better and long-lasting immune response. Therefore, the intranasal vaccine could be used as a combination with the intramuscular Covaxin shot.

 

“While the nasal vaccine can be administered as two shots, the company is testing whether combining it with Covaxin gives better results. Thus, this can be used as a mix-and-match with Covaxin to produce a more holistic immune response,” the source said.

 

The company did not answer some queries sent by Business Standard till the time of going to press.

 

The two vaccines have different mechanisms of action and trigger slightly different immune responses.

 

Shahid Jameel, senior virologist and director at Ashoka University, said a different kind of antibodies protects the nasal mucosa – these are called IgA antibodies. “This is not sufficiently generated when a vaccine is administered through the intramuscular route,” Jameel said.

 

Commenting on the nasal vaccine, Jacob John, former head of Centre for Advanced Research in Virology at the Indian Council of Medical Research (ICMR), said to have a nasal vaccine is a ‘fantastic idea’ for two reasons — one, it can potentially create sterile immunity, and two, it is easy to administer and thus scalable.

 

Experts feel that when one gets sterile immunity in the nasal tract, one does not shed the virus, and this prevents transmission.

 

According to sources in the know, recruitments for the phase 2 trials are over. Around 650 volunteers are likely to be part of the trials. The first phase had 175 participants.

 

Meanwhile, Bharat Biotech has also finished administering the vaccines for its paediatric trial of Covaxin. Now, it is analysing the data before it can submit it to the regulator for review.

 

BOOSTER DOSE

Three-legged phase 2 trials will be done:

  • Two shots of intranasal vaccine BBV154 in 28-day interval
  • Covaxin as first dose followed by BBV154 
  • BBV154 as first dose followed by Covaxin


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.

Read More on

BHARAT BIOTECH

CORONAVIRUS VACCINE

NASAL VACCINE

ICMR

CURRENT AFFAIRS

NEWS


Most Read

Markets

Companies

Opinion

Latest News

Todays Paper

News you can use